SEC filing · 8-K

Biomarin Pharmaceutical Inc: Material agreement

BioMarin entered into a settlement and license agreement with Ascendis Pharma to resolve patent litigation and receive product royalties.

Filed September 30, 2026

Positive for the company

What happened

On September 24, 2026, BioMarin signed a Settlement and License Agreement with Ascendis Pharma, effective as of August 28, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Biomarin Pharmaceutical Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.